Physician profile
Tina Mitchell
NPI 1437128485
$635.04
in general payments reported to CMS, 2019-2025
12 companies · $95.84 in 2025
The $95.84 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $27.31 · 2021: $38.53 · 2022: $123 · 2023: $75.66 · 2024: $101 · 2025: $95.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.95 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $231.53 | 2021-2025 | |
| Astellas Pharma US INC | $99.96 | 2024-2025 | Veozah |
| Allergan, INC. | $60.02 | 2019 | |
| Abbvie INC. | $39.38 | 2019-2020 | |
| Boston Scientific Corporation | $35.95 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.33 | 2025 | |
| Lupin INC. | $30.83 | 2019 | |
| Therapeuticsmd, INC. | $28.92 | 2019 | |
| Exeltis, USA INC. | $25.99 | 2022 | |
| Avion Pharmaceuticals | $25.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.64 | 2019 | |
| Aspira Women'S Health INC | $5.75 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.